Inhibitors of hepatitis C virus

A compound having the structure:

• wherein:
• is selected from the group consisting of
• R1 is selected from the group consisting of hydrogen, halide, —CF3, —CN, —C(O)H, —C(O)OR6—, —C(O)NHR7, —C(O)N(OH)R7, —C(═NOMe)NHR7, C(═NOH)NHR7, —CH(CF3)NHR8, —CH(CN)NHR9, —S(O)2NHR10, —C(═NCN)NHR11,
• R2 is substituted or unsubstituted aryl or heteroaryl;
• R6 is selected from the group consisting of hydrogen, allyl, C1-4 alkyl, cyclopropyl, and benzyl;
• R7 is selected from the group consisting of hydrogen, C1-4 alkyl, cyclopropyl, C1-4 alkoxy, cyclopropoxy, alkylsulfonyl, and cycloalkylsulfonyl;
• R8, R9, R10 and R11 are each independently selected from the group consisting of hydrogen, C1-4 alkyl, cyclopropyl, C1-4 alkoxy, and cyclopropoxy;
• and
• R17 is selected from the group consisting of H, F, Cl and CN;
• or a pharmaceutically acceptable salt thereof.